These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 8064890

  • 1. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
    Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, Cordon-Cardo C.
    J Natl Cancer Inst; 1994 Sep 07; 86(17):1325-30. PubMed ID: 8064890
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.
    Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine AJ.
    Cancer Res; 1994 Feb 01; 54(3):794-9. PubMed ID: 8306343
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
    Osman I, Scher HI, Zhang ZF, Pellicer I, Hamza R, Eissa S, Khaled H, Cordon-Cardo C.
    Clin Cancer Res; 1997 Apr 01; 3(4):531-6. PubMed ID: 9815716
    [Abstract] [Full Text] [Related]

  • 6. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
    Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu WJ, Takahashi R, Sugiyama T, Yoshida O.
    J Natl Cancer Inst; 1994 Sep 07; 86(17):1331-5. PubMed ID: 8064891
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
    Olsson H, Hultman P, Rosell J, Söderkvist P, Jahnson S.
    BMC Urol; 2013 Jan 28; 13():5. PubMed ID: 23356517
    [Abstract] [Full Text] [Related]

  • 10. p53 Mutation and MDM2 amplification in human soft tissue sarcomas.
    Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B.
    Cancer Res; 1993 May 15; 53(10 Suppl):2231-4. PubMed ID: 8387391
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
    Foulkes WD, Stamp GW, Afzal S, Lalani N, McFarlane CP, Trowsdale J, Campbell IG.
    Br J Cancer; 1995 Oct 15; 72(4):883-8. PubMed ID: 7547235
    [Abstract] [Full Text] [Related]

  • 13. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
    Pfister C, Larue H, Moore L, Lacombe L, Veilleux C, Tetu B, Meyer F, Fradet Y.
    Int J Cancer; 2000 Jan 20; 89(1):100-4. PubMed ID: 10719738
    [Abstract] [Full Text] [Related]

  • 14. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C, Moore L, Allard P, Larue H, Lacombe L, Têtu B, Meyer F, Fradet Y.
    Clin Cancer Res; 1999 Dec 20; 5(12):4079-84. PubMed ID: 10632343
    [Abstract] [Full Text] [Related]

  • 15. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
    Molina P, Pellín A, Navarro S, Boix J, Carda C, Llombart-Bosch A.
    Virchows Arch; 1999 Dec 20; 435(6):596-605. PubMed ID: 10628802
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.